Aprea Therapeutics, Inc. – NASDAQ:APRE
Aprea Therapeutics stock price today
Aprea Therapeutics stock price monthly change
Aprea Therapeutics stock price quarterly change
Aprea Therapeutics stock price yearly change
Aprea Therapeutics key metrics
Market Cap | 16.84M |
Enterprise value | N/A |
P/E | -0.06 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.27 |
PEG ratio | N/A |
EPS | -3.32 |
Revenue | 963.8K |
EBITDA | -14.03M |
Income | -12.71M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1456.71% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAprea Therapeutics stock price history
Aprea Therapeutics stock forecast
Aprea Therapeutics financial statements
| Jun 2023 | 249.68K | -3.25M | -1305.27% |
|---|---|---|---|
| Sep 2023 | 319.46K | -3.20M | -1003.08% |
| Dec 2023 | 14.07K | -3.44M | -24463.62% |
| Mar 2024 | 380.56K | -2.81M | -738.39% |
| Mar 2024 | 380.56K | -2.81M | -738.39% |
|---|---|---|---|
| Sep 2025 | 14.07K | -971.53K | -6902.56% |
| Oct 2025 | 380.56K | -914.39K | -240.27% |
| Dec 2025 | 380.56K | -1.03M | -273.14% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 28680668 | 5.26M | 18.35% |
|---|---|---|---|
| Sep 2023 | 25766423 | 5.47M | 21.26% |
| Dec 2023 | 22650174 | 4.38M | 19.36% |
| Mar 2024 | 33200006 | 2.96M | 8.93% |
| Jun 2023 | -3.21M | 24.84K | -24.84K |
|---|---|---|---|
| Sep 2023 | -2.24M | -84.07K | -86.59K |
| Dec 2023 | -3.86M | -8.55K | 86.37K |
| Mar 2024 | -3.93M | -7.97K | 14.70M |
Aprea Therapeutics alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 9 |
| Apr 2024 | 9 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Aprea Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 10097 | 0 |
| Mar 2024 | 33460 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Common Stock | 1,010 | $7.29 | $7,363 | ||
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Common Stock | 1,010 | $7.29 | $7,363 | ||
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Tranche A Warrant | 505 | N/A | N/A | ||
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Tranche A Warrant | 505 | N/A | N/A | ||
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Tranche B Warrant | 505 | N/A | N/A | ||
Purchase | HAMILL JOHN P. officer: SrVP/CFO.. | Tranche B Warrant | 505 | N/A | N/A | ||
Purchase | SEIZINGER BERND R. director | Common Stock | 6,860 | $7.29 | $50,009 | ||
Purchase | SEIZINGER BERND R. director | Tranche A Warrant | 3,430 | N/A | N/A | ||
Purchase | SEIZINGER BERND R. director | Tranche B Warrant | 3,430 | N/A | N/A | ||
Purchase | HENNEMAN JOHN B III director | Common Stock | 6,860 | $7.29 | $50,009 |
-
What's the price of Aprea Therapeutics stock today?
One share of Aprea Therapeutics stock can currently be purchased for approximately $1.58.
-
When is Aprea Therapeutics's next earnings date?
Unfortunately, Aprea Therapeutics's (APRE) next earnings date is currently unknown.
-
Does Aprea Therapeutics pay dividends?
No, Aprea Therapeutics does not pay dividends.
-
How much money does Aprea Therapeutics make?
Aprea Therapeutics has a market capitalization of 16.84M.
-
What is Aprea Therapeutics's stock symbol?
Aprea Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "APRE".
-
What is Aprea Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aprea Therapeutics?
Shares of Aprea Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aprea Therapeutics's key executives?
Aprea Therapeutics's management team includes the following people:
- Mr. Christian S. Schade Pres, Chief Executive Officer & Chairman(age: 64, pay: $798,250)
- Dr. Eyal C. Attar M.D. Senior Vice President & Chief Medical Officer(age: 54, pay: $630,360)
- Mr. Scott M. Coiante Senior Vice President, Company Sec. & Chief Financial Officer(age: 58, pay: $512,450)
-
How many employees does Aprea Therapeutics have?
As Jul 2024, Aprea Therapeutics employs 7 workers, which is 22% less then previous quarter.
-
When Aprea Therapeutics went public?
Aprea Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 3 Oct 2019.
-
What is Aprea Therapeutics's official website?
The official website for Aprea Therapeutics is atrinpharma.com.
-
Where are Aprea Therapeutics's headquarters?
Aprea Therapeutics is headquartered at 535 Boylston St., Boston, MA.
-
How can i contact Aprea Therapeutics?
Aprea Therapeutics's mailing address is 535 Boylston St., Boston, MA and company can be reached via phone at +61 74639385.
Aprea Therapeutics company profile:
Aprea Therapeutics, Inc.
atrinpharma.comNASDAQ
7
Biotechnology
Healthcare
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Boston, MA 02116
CIK: 0001781983
ISIN: US03836J2015
CUSIP: 03836J102
